- Home
- ZYME vs XXI Comparison
ZYME vs XXI Comparison
Compare ZYME & XXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZYME | XXI |
|---|---|---|
| Founded | 2003 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZYME | XXI |
|---|---|---|
| Price | $26.76 | $8.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $38.90 | N/A |
| AVG Volume (30 Days) | 517.9K | ★ 1.1M |
| Earning Date | 05-07-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $10.89 | $5.61 |
| 52 Week High | $29.75 | $11.49 |
Technical Indicators
Market Signals| Indicator | ZYME | XXI |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 72.78 |
| Support Level | $22.28 | $8.66 |
| Resistance Level | $27.35 | $9.97 |
| Average True Range (ATR) | 1.03 | 0.39 |
| MACD | -0.23 | 0.13 |
| Stochastic Oscillator | 11.52 | 88.03 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc has no operation history.